Contact Us

Phone
Alison Hey-Cunningham +61 2 9515 6651    

Email
alison.hey-cunningham@sydney.edu.au

Address
Centre of Research Excellence in Pulmonary Fibrosis
Respiratory Medicine and Sleep Unit
Level 11, Royal Prince Alfred Hospital
Camperdown NSW 2050

Facebook

Twitter

Online Enquiry

* Required fields

Publications

2020

Glenn LM, Corte TJ. Diagnosing idiopathic pulmonary fibrosis: Has the time for surgical lung biopsy passed? Respirology 2020. doi: 10.1111/resp.13909. 

Teoh AKY, Jo HE, Chambers DC, Symons K, Walters EH et al. Blood monocyte counts as a potential prognostic marker for IPF: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal 2020, 55:1901855. doi: 10.1183/13993003.01855-2019.

Khor YH, Holland AE, Goh NSL et al. Ambulatory oxygen in fibrotic interstitial lung disease: A pilot, randomised, triple-blinded, sham-controlled trial. Chest 2020, 158 (1): 234-244. doi: 10.1016/j.chest.2020.01.049.

Tikellis G, Lee JYT, Corte TJ, Maloney J et al. Peer Connect Service for people with PF in Australia: Participants' experiences and process evaluation. Respirology 2020. doi: 10.1111/resp.13807.

Lee JYT, Tikellis, G, Corte TJ et al. The supportive care needs of people living with pulmonary fibrosis and their caregivers: A systematic review.

Teoh AKY, Glaspole I, Macansh S, Corte TJ. Importance of occupational exposure data: A national idiopathic pulmonary fibrosis registry perspective. American Journal of Respiratory and Critical Care Medicine 2020 May 1;201(9):1165-1167. doi: 10.1164/rccm.201911-2242LE.

Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA et al. Diagnostic accuracy of transbronchial lung cryobiopsy for Interstitial Lung Disease diagnosis (COLDICE): A prospective, comparative study. The Lancet Respiratory Medicine 2020, 8(2):171-181. doi: 10.1016/S2213-2600(19)30342-X.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T et al. Acute exacerbation of Idiopathic Pulmonary Fibrosis: International survey and call for harmonisation. European Respiratory Journal 2020, 55(4). doi: 10.1183/13993003.01760-2019.

2019

Khor YH, Goh N, Miller B, Glaspole I, Holland AE, McDonald CF. A pilot randomised, controlled trial of ambulatory oxygen versus air via portable concentrator in fibrotic interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 2019, 199.

Khor YH, Goh NSL, Miller B, Glaspole I, Holland AE, McDonald CF. Exertional desaturation and prescription of ambulatory oxygen therapy in ILD. Respiratory Care 2019, 64(3):299-306. doi: 10.4187/respcare.06334.

Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S et al. Implications of the diagnostic criteria of IPF in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology 2019, 24(4):361-368. doi: 10.1111/resp.13427. 

Culver DA, Behr J, Belperio JA, Corte TJ et al. Patient registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2019, 200(2):160-167. doi: 10.1164/rccm.201902-0431CI.

Burnett K, Glaspole I, Holland AE. Understanding the patient's experience of care in Idiopathic Pulmonary Fibrosis. Respirology 2019, 24(3):270-277. doi: 10.1111/resp.13414.

Hoffman M, McDonald C, Corte T, Chambers D, Ekstrom M, Glaspole I, Goh N, Holland A. Effective delivery of ambulatory oxygen in interstitial lung disease - a crossover trial. European Respiratory Journal 2019, 54:2. doi: 10.1183/13993003.congress-2019.PA1226.

Holland AE, Lee J, Maloney J, Walsh J. Sharing experiences and offering mutual support: An evaluation of the Peer Connect Service for people with pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2019, 199:2.

Holland A, Lee J, Maloney J, Walsh J. Shared experiences, mutual support: Peer Connect Service for Pulmonary Fibrosis. Respirology 2019, 24:33.

Khor YH, Barnes H, NG Y, Goh N, McDonald CF, Holland AE. Prognosis of adults with idiopathic pulmonary fibrosis without effective therapies: A systematic review and meta-analysis. American Journal of Respiratory and Critical Care Medicine 2019, 199:2.

Clynick B, Jo H, Corte T, Glaspole I, Grainge C, Hopkins P et al. Differences in circulating nucleic acids between patients with stable and progressive lung function in Idiopathic Pulmonary Fibrosis. Respirology 2019, 24:35.

Clynick B, Jo H, Corte T, Glaspole I, Grainge C, Hopkins P et al. Circulating RNA differences between patients with stable and progressive lung function in Idiopathic Pulmonary Fibrosis. European Respiratory Journal 2019, 54(5):CP8. doi: 10.1183/13993003.02115-2018.

Glaspole I, Lancaster L, Hernandez P, Inoue Y et al. Nintedanib in patients with Idiopathic Pulmonary Fibrosis: Safety and tolerability. Respirology 2019, 24:34.

Hatch M, Goh N, Khor Y. Baseline inflammatory markers and survival in patients with Interstitial lung disease. Respirology 2019, 24:167.

2018

Glaspole I, Wells A, Behr J, Stansen W, Stowasser S, Maher T. Composite physiologic index in Idiopathic Pulmonary Fibrosis: Effects of nintedanib. Respirology 2018 23:125.

Barnes H, Goh N, Westall G, Holland A, Glaspole I. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Respirology 2018 23:124.

Abramson, MJ, Murumbadoro T, Alif SM, Benke G et al. Occupational and environmental risk factors for Idiopathic Pulmonary Fibrosis in Australia. European Respiratory Journal 2018 52. doi: 10.1183/13993003.congress-2018.PA5068.

Waters DW, Blokland KEC, Pathinayake PS, Burgess JK, Mutsaers SE, Prele CM, Schuliga M, Grainge CL, Knight DA. Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018 Apr 26. doi: 10.1152/ajplung.00037.2018.

Jo HE and Corte TJ. Idiopathic Pulmonary Fibrosis. Australian Doctor 6 April 2018; 17-24. https://www.howtotreat.com.au/node/47341/1.

Griffiths K, Habiel DM, Jaffar J, Binder U, Darby WG, Hosking CG, Skerra A, Westall GP, Hogaboam CM, Foley M. Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis. Scientific Reports (2018) 1, 3212. doi: 10.1038/s41598-018-20811-5.

Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, NĂ¼ssing S, Fox A, Chung AW, Laurie KL, Hurt AC, Rockman S, Lappas M, Loudovaris T, Mannering SI, Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO, Kedzierska K. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. American Association for the Advancement of Science (2018) 10, 428. doi: 10.1126/scitranslmed.aan8405.

Pizzolla A, Nguyen TH, Sant S, Jaffar J, Loudovaris T, Mannering SI, Thomas PG, Westall GP, Kedzierska K, Wakim LM. Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. Journal of Clinical Investigations (2018) 128 (2):721-733.

2017

Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Lake F, Hopkins PMA, Corte TJ, Allan H and Glaspole IN. The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.  Respirology (2017) 22, 1459-1472. doi:10.1111/rep.13163.

 Jo HE, Troy LK, Keir G, Chambers DC, Holland A, Goh H, Wilsher M, De Boer S, Moddley Y, Grainge C, Whitford H, Chapman S, Reynolds PN, Glaspole I, Beatson D, Jones L, Hopkins P and Corte TJ. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology (2017) 22, 1436-1458. doi:10.1111/resp.13146.

Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, Jones LJ, Hopkins P, Allan HM, Glaspole I and Corte TJ. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and the Lung Foundation Australia position statement summary.  Med J Aust 2017; 207(11):1 doi:10.5694/mja17.00799.

Glaspole I.G, Watson A.L, Allan H, Chapman S, Cooper W.A, Corte T.J,Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y,  Reynolds P.N, Ryerson C.J, Walters E.H,  Zappala CJ and Holland A.E. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. European Respiratory Journal (2017) 50: 1700168. http://erj.ersjournals.com/content/50/2/1700168.long

Glaspole I.N,  Chapman S.A.,  Cooper W.A.,  Ellis S.J.,  Goh N.S., Hopkins P.M, Macansh S., Mahar A., Moodley Y.P., Reynolds P.N., Walters E.H.,  Zappala C.J.  and Corte T.J. Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology (2017) doi: 10.1111/resp.12989 http://onlinelibrary.wiley.com/doi/10.1111/resp.12989/full

Jo H.E, Glaspole I., Grainge C., Goh N., Hopkins P.M.A, Moodley Y., Reynolds P.N.,  Chapman, S.E. Walters H.E, Zappala C., Allan A., Keir G.J., Hayen A., Cooper W.A., Mahar A.M, Ellis S., Macansh S., and Tamera J. Corte. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal (2017) 49 1601592. http://erj.ersjournals.com/content/49/2/1601592